Celebrating 60 years of melanoma research to save lives

19 April 2017
Melanoma Institute Australia is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
It was back in 1957 when Sydney Hospital recorded its first data on a melanoma patient. This patient record marked the beginning of what was to become the Melanoma Research Database (MRD), which is now the biggest database of its kind in the world. With more than 41,000 patient records, the MRD continues to play a vital role in underpinning the ground-breaking work of Melanoma Institute Australia (MIA) and around the world.
“Melanoma used to be viewed as a disease with a dismal outlook for patients, but I am pleased to say that today things are much different,” said Professor Richard Scolyer, MIA’s Conjoint Medical Director. “The foresight of our colleagues at Sydney Hospital to start recording patient data back in 1957 set us on a path towards greater understanding of the disease, and we are now leading the world in advancing melanoma treatment and research.”
“Life expectancy for advanced melanoma patients has tripled in the last five years, and we are even seeing some patients who are recovering fully,” comments Professor Georgina Long, MIA’s Conjoint Medical Director. “However we still have a long way to go, with one Australian dying from melanoma every six hours.”
Critical to our story is the work of Professor Gerry Milton (pictured) of the Sydney Melanoma Unit (now Melanoma Institute Australia) who in 1968 was trying to better understand the disease. He recruited Dr Helen Shaw to collect and collate all the records of melanoma patients treated at Sydney Hospital over the previous decade. Always forward thinking, the Unit decided to embrace the “high technology” of the day and convert the entire patient catalogue to punch cards – and so the database was born. The detailed patient records included diagnosis, treatment and disease course over time.
The MRD database is now managed by a team including IT specialists and clinical data managers, dedicated to its refinement, preservation and cultivation. It serves as an invaluable resource to identify and extract specific sub-sets of information for research projects related to causes, diagnosis, prognosis and treatment outcomes in melanoma patients. The knowledge gained from these studies assists in the management of melanoma patients around the world.
“We celebrate this Diamond Anniversary with much gratitude to our professional predecessors for their pioneering work that was way ahead of its time. We also have immense appreciation for those thousands of melanoma patients who over the last 60 years have allowed their clinical records to be included in our research database which have enabled us to improve the lives of melanoma patients that have followed them,” Professor Scolyer said.
“They have quite literally given the gift of life to other melanoma patients, and will be the unsung heroes when we finally achieve our goal of ending melanoma.”

Congratulations to Professor Georgina Long
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).

Uniting our global researchers for melanoma
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.

Best practice guidelines for melanoma care go digital
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.

Awards and honours for our talented researchers
Congratulations are in order for two of our talented researchers.

5 Minutes With Prof Richard Scolyer
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.

Research spotlight: High Risk Clinic
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.

Learning from the best in the world
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.

Uniting the world for a cure
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients

A Day in the Life of... Michelle Peranec
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.

Wildfire Award helps ignite new melanoma research
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.

Opinion: Fighting the Resistance
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.

5 Minutes With A/Prof Jennifer Wargo
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.

Dr James Wilmott awarded for outstanding cancer research
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.

Community invests in MIA's new trial
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.

New trial giving options
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.

Melanoma research summary from ASCO
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.

Updated privacy policy
We value your privacy and want you to be familiar with how we collect, use and disclose your information.

Can cognitive technology assist with melanoma identification?
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.

'4 Questions With...' Series
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.

Stop the Spread campaign shortlisted
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.